Abstract
Cardiac amyloidosis is a complex and vexing clinical condition that requires a high degree of suspicion for the diagnosis with a substantial amount of discipline to discern the extent of disease and the best available therapy. There is a complex interplay between multiple organ systems, and the clinical presentation may involve a myriad of confusing clinical symptoms. The diagnosis of cardiac amyloidosis can be confirmed with a combination of physical findings, cardiac biomarkers, noninvasive testing, and, if necessary, myocardial biopsy. Genetic testing is critical to establish the type of amyloidosis.
Original language | English (US) |
---|---|
Pages (from-to) | 409-416 |
Number of pages | 8 |
Journal | Heart Failure Clinics |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1 2017 |
Externally published | Yes |
Keywords
- Cardiac amyloidosis
- Cardiotoxicity
- Immunomodulatory drugs
- Multiple myeloma
- Proteasome inhibitors
- TTR
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine